Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharm Exam 2 > Bannon: Antipsychotic Drugs > Flashcards

Bannon: Antipsychotic Drugs Flashcards

1
Q

Schizophrenia

Epidemiology:

A
  • Affect 1% of the population worldwide
  • 30% of all homeless people
  • 30% of all hospitalizations

.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q 
Schizophrenia
Psychotic Symptoms (Positive/Cognitive Symptoms): (3)
A

Psychotic Symptoms (Positive/Cognitive Symptoms): emerge in late teens
o Loss of reality
o Delusions and hallucinations (usually auditory)
o Disordered thinking and memory
.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q 
Schizophrenia
Prodromal Signs (Negative Symptoms): (5)
A 
Prodromal Signs (Negative Symptoms): poorer prognosis associated with prominent negative symptoms
o	Social isolation and withdrawal
o	Poverty of speech
o	Odd behavior/ideas
o	Blunted affect
o	Lack of motivation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Schizophrenia

Biological Findings: (3)

A

Biological Findings: especially associated with negative symptoms

  • Decreased blood flow in frontal lobe and caudate during working memory tasks
  • Reduced hippocampal and medial temporal lobe volume
  • Enlarged ventricles
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Schizophrenia

Genetic Predisposition:

A

15% incidence in first degree relatives (compared to 1% incidence in the general population)

17% concordance in DZ twins; ~50% concordance in MZ twins

Complex polygenic disorder (as evidenced by high frequency and partial penetrance)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Schizophrenia
Dopamine Hypothesis

Evidence for the Involvement of DA: (3)

A
  1. Dopamine agonists can induce/exacerbate psychosis
  2. Clinically effective APDs block DA receptors
  3. DA receptor expression increased in schizophrenia (has since been proven UNTRUE)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Dopamine Receptors:

A

Dopamine Receptors: G-protein coupled receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

D1 Family includes:

A

D1 Family: includes D1 and D5 (less prominent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

D1 Family

Location:

A

Location:

  • D1: striatum and neocortex*
  • D5: hippocampus and hypothalamus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q 
D1 Family
Second Messengers (Gq):
A

Second Messengers (Gq):

  • Increase cAMP
  • Increase PIP2 hydrolysis (PKC activation and Ca++ mobilization)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

D2 Family includes:

A

D2 Family: D2, D3 and D4 (latter 2 less prominent)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

D2 Family

Location:

A

D2: striatum, substantia nigra and pituitary gland*

D3: olfactory tubercle, nucleus accumbens, hypothalamus

D4: frontal cortex, medulla, midbrain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q 
D2 Family
Second Messengers (Gi):
A

Decrease cAMP

Increase K+ currents

Decrease voltage-gated Ca++ currents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dopamine Pathways: single source divergent systems

Nigrostriatal DA:
Mesolimbic DA:

A

Nigrostriatal DA: modulates movement and learned habits; 80% of total DA

Mesolimbic DA: modulates motivation, goal-directed thinking, affect and reward

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Dopamine Pathways: single source divergent systems

Mesocortical DA:
Hypothalamic DA:
Area postrema:

A

Mesocortical DA: modulates cognition

Hypothalamic DA: hormone regulation

Area postrema: located outside the BBB; mediates emesis (very sensitive to DA drugs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dopamine Pathways and their Relation to Psychotic Symptoms

Mesolimbic/Mesocortical DA:

A

Mesolimbic/Mesocortical DA: overactive –>possibly related to positive Sx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Dopamine Pathways and their Relation to Psychotic Symptoms

Mesocortical DA:

A

Mesocortical DA: hypofunction –> possibly related to negative Sx (DA blockade not helpful for these)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Dopamine Pathways and their Relation to Psychotic Symptoms

Nigrostriatal DA:

A

Nigrostriatal DA: highest DA content and related to extrapyramidal (motor) SEs and tardive dyskinesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dopamine Pathways and their Relation to Psychotic Symptoms

Tuberoinfundibular/Hypothalamic DA:

A

Tuberoinfundibular/Hypothalamic DA: related to endocrine effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

D2R Blockade and Clinical Efficacy:

A

D2R Blockade and Clinical Efficacy: strong correlation between blockage for these R and efficacy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Original D2 Blocking Agents (ie. Chlorpromazine):

A

Original D2 Blocking Agents (ie. Chlorpromazine): not a real high affinity for D2 receptors and therefore needed very high doses to achieve desired effects (lots of SE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Newer D2 Blocking Agents with Higher Affinity (ie. Spiroperidol):

A

Newer D2 Blocking Agents with Higher Affinity (ie. Spiroperidol): although higher affinity, do not have improved efficacy over earlier agents; however, will have different SE profiles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Commonality in APDs Relevant to Antipsychotic Effects
Possibilities

5HT2A:
D4 in cortex:

A

5HT2A: typical APDs occupy most striatal D2 receptors while atypical APDs occupy a lower proportion of D2 R and more 5HT2A; however, role for 5HT2A receptors in psychosis not clear

D4 in cortex: but not all block here (ie. quetiapine)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Commonality in APDs Relevant to Antipsychotic Effects
Possibilities

Fast dissociation relative to R binding allows better modulation of function (ie. high Kd at D2):

A

Fast dissociation relative to R binding allows better modulation of function (ie. high Kd at D2): but then atypical APDs should look like low-affinity typical APDs (not the case)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Commonality in APDs Relevant to Antipsychotic Effects

Another issue:

A

Another issue: blockade of receptors is immediate but effects are delayed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Commonality in APDs Relevant to Antipsychotic Effects

BOTTOM LINE:

A

Antipsychotic MOA(s) still not really understood

However, D2 DA receptor blockade is a commonality to all agents

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Pharmacokinetics of APDs

Absorption:

A

Absorption: most are READILY but INCOMPLETELY absorbed

  • Highly lipid soluble and protein bound
  • Long clinical duration relative to plasma half life
28
Q

Pharmacokinetics of APDs

Administration:

A

Administration: parenteral forms (IM depot injections) available (especially older APDs); often used when compliance is an issue

29
Q

Pharmacokinetics of APDs

Metabolism:

A

Metabolism: significant FIRST PASS metabolism by P450; conjugation for urinary excretion

30
Q

Adverse Effects of APDs: (6)

A

Relatively high therapeutic index: pretty safe in overdose

Autonomic Effects

Cardiovascular Effects:

Endocrine Effects

Metabolic Effects

Extrapyramidal Effects:

31
Q

Adverse Effects of APDs

Relatively high therapeutic index:

A

Pretty safe in overdose

32
Q

Adverse Effects of APDs
Autonomic Effects

Muscarinic Block:
Alpha Adrenergic Blockade (α1):

A

Muscarinic Block: dry mouth, urinary retention, constipation

Alpha Adrenergic Blockade (α1): orthostatic hypotension, impotence

33
Q

Adverse Effects of APDs
Cardiovascular Effects

Phenothiazines (chlorpromazine and others):
Atypical APDs (esp. ziprasidone):
Overall:

A

Phenothiazines (chlorpromazine and others): ↑HR, abnormal ECG

Atypical APDs (esp. ziprasidone): significant risk of QT prolongation

Overall: ~2x increased risk of sudden cardiac death with both typical and atypical (dose-dependent)

34
Q

Adverse Effects of APDs
Endocrine Effects

Hyperprolactinemia:

A

Hyperprolactinemia: manifest as amenorrhea, galactorrhea, infertility, impotence
- Due to decreased action of DA (normally suppresses prolactin release from anterior pituitary)

35
Q

Adverse Effects of APDs
Metabolic Effects

Atypical APDs (esp. clozapine and olanzapine): 
Possible cause:
A 
Atypical APDs (esp. clozapine and olanzapine): weight gain leading to insulin resistance and diabetes
-	Possible cause: H1 and 5HT blockade
36
Q

Adverse Effects of APDs

Extrapyramidal Effects:

A

Seen in proportion to D2R affinity (drugs with higher affinity for this receptor cause more EP effects)

Some effects are short term and limiting, while others are long-term and irreversible

37
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)

Early Adverse Effects: (4)

A

Acute Dystonic Reaction
Akathisia
Parkinsonism
Neuroleptic Malignant Syndrome

38
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)

Acute Dystonic Reaction:

A

Acute Dystonic Reaction: of face or back (1-5 days after starting medication); NOT seizures or hysteria

39
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)

Akathisia:

A

Akathisia: uncontrollable restlessness (5-60 days after starting medication); NOT agitation

40
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)

Parkinsonism:
Treatment of Acute Dystonic Reaction/Akathisia/Parkinsonism: (2)

A

Parkinsonism: looks like idiopathic PD (5-30 days after starting medication)

Treatment of Acute Dystonic Reaction/Akathisia/Parkinsonism:

  • Reduce dose of APD
  • Anti-muscarinics/anti-histaminics (bring system back into balance by reducing ACh)
41
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)

Neuroleptic Malignant Syndrome:
When:

A

Neuroleptic Malignant Syndrome: very rare sensitivity to DA blockade by all types of APDs

When: first few weeks of taking medication OR after increasing dose

42
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)
Neuroleptic Malignant Syndrome

Manifestations: (3)

A

Hypothalamic DA block leads to very high dangerous fever

Basal ganglia DA block leads to parkinsonism

Others symptoms include autonomic instability and muscle breakdown

43
Q

Adverse Neurological Effects of APDs (Extrapyramidal Effects)
Neuroleptic Malignant Syndrome

Treatment:

A

Bromocriptine (DA agonist) and dantrolene

44
Q

Late Adverse Effects

Tardive Dyskinesia:

A

Tardive Dyskinesia: occurs months to years after starting medication

Most important side effect of APDs (20-40% of patients chronically treated with typical will develop TD)

Advanced cases are difficult to reverse (early recognition is important)

Masked by increasing APD dose and worsens upon drug withdrawal

45
Q

Special Adverse Effects with Clozapine: (2)

A

Seizures (1-4% of patients)

Agranulocytosis (1-2% of patients)

  • Potentially fatal
  • Develops between weeks 6-18 and reversible if caught early
  • Therefore, need to do weekly blood counts for the first 6 months and every 3 weeks after that
46
Q

CATIE Study
Basics:
Phase I:

A

Basics: first generation perphenazine vs. second generation olanzapine, quetiapine, risperidone and ziprasidone

Phase I:

  • ¾ of patients switched mediations because of adverse side effects
  • Olanzapine showed a modest advantage in terms of duration of treatment and symptom relief (but substantial weight-related SEs)
  • Other atypicals (second generation) showed no advantage over perphenazine
47
Q

CATIE Study

Phase II:

A

Patients who stopped APDs due to SEs/no response (and who refused to take clozapine) given one of the 4 atypicals mentioned above
- Patients continued on olanzapine and risperidone significantly longer

Patients who stopped APDs because of inadequate symptom relief were given clozapine, olanzapine, risperidone or quetiapine
- Clozapine significantly more effective and patients stayed on it longer

48
Q

CATIE Study

Issues with the Study:

A

Subject selection limitation (most patients had no EPS/TD and those that had TD were assigned to second generation APDs only)

Therefore, study deals with side effects and efficacy but does not really address the issue of tardive dyskinesia

49
Q

CUtLASS Study:

Basics:

A

Basics:

  • Clinicians and patients UNBLINDED and initiated drug changes (better mimicked the clinical situation BUT less control of variables)
  • Assessed by a blind rater after 1 year on the medications
50
Q

CUtLASS Study:

Overall Results:

A

Overall Results:

  • Typicals and atypicals equivalent in quality of life, efficacy and side effects
  • Clozapine better in managing symptoms than other second generation drugs in treatment resistance patients (overall quality of life also somewhat better)
51
Q

TEOSS Study

Basics:

A

Basics:

  • Study of young patients on APDs (8-19 years old)
  • Looked at olanzapine, risperidone or molindone PLUS benztropine (anticholinergic)
52
Q

TEOSS Study

Overall Results:
Side effects differed:

A

Overall Results:Roughly equivalent efficacy

Side effects differed:

  • Weight gain (olanzapine>risperidone>molindone)
  • Increase in cholesterol and other metabolic disturbances (olanzapine- this arm of the trial was terminated)
53
Q

Determining the DOC for your Patient

Cost:
Adverse Side Effects:
Compliance:
Treatment-resistance

A

Cost: newer atypicals 10-100x more costly than generics

Adverse Side Effects: profile of typical vs. atypical; short term vs. long term use

Compliance: depot injections or drug changes

Treatment-resistance

54
Q

Chlorpromazine (and other phenothiazines)

Receptor Affinities:
Pros: (1)
Cons: (2)

A

Receptor Affinities: α1=5HT2A>D2=D4=H1>D1=M

Pros: Generic and inexpensive

Cons:

  • Many adverse autonomic effects (dirty drug- action at many different receptors)
  • Some risk of EPS and TD (action at D2 receptors)
55
Q

Haloperidol

Receptor Affinities:
Pros: (3)
Cons: (1)

A

Receptor Affinities: D2>α1>D4>5HT2A>D1»H1»M

Pros:

  • Generic and inexpesive
  • Parenteral form available (depot injection)
  • Less autonomic effects (does not have a high affinity for these receptors)

Cons:
- Strong D2 block means higher risk of EPS and TD

.

56
Q

Risperidone

Receptor Affinities:
Pros: (4)
Cons: (1)

A

Receptor Affinities: 5HT2A>D2=α1>D4>H1>D1»M

Pros:

  • Generic and inexpensive
  • Depot preparation available
  • Borderline atypical and therefore LESS 5HT-related weight gain compared to other atypicals
  • More tolerable than most others APDs (maybe)

Cons:
- Borderline atypical and therefore MORE DA-related side effects (hyperprolactinemia, EPS)

57
Q

Olanzapine

Receptor Affinities:
Pros: (3)
Cons: (2)

A

Receptor Affinities: 5HT2A=M>H1>D4>D2>α1>D1

Pros:

  • More tolerable than other APDs (clozapine-like structure without risk for agranulocytosis or seizures)
  • May be somewhat more effective than other APDs (subtle)
  • Less risk of EPS and TD (less action at D2)

Cons:

  • Expensive (no generic)
  • Several metabolic adverse effects including weight gain and diabetes (more action at 5HT2A)
58
Q

Clozapine

Receptor Affinities:
Pros: (2)
Cons: (3)

A

Receptor Affinities: 5HT2A>D4=α1=M=H1>D2>D1

Pros:

  • Clearly the most efficacious drug available for refractory cases
  • Less risk for EPS and TD (less action at D2)

Cons:
- Expensive (no generic)
- Risk for weight gain and diabetes (more action at 5HT2A)
- More serious side effects of agranulocytosis and seizures
.

59
Q

Traditional Use of APDs

Schizophrenia:
Schizoaffective Disorder:

A

Schizophrenia: primary indication

Schizoaffective Disorder:

  • Characteristics of schizophrenia PLUS affective disorders (depression, BPD)
  • Treat with APD plus antidepressants, lithium or valproate
60
Q

Traditional Use of APDs

Neuroleptoanesthesia:
Pre-Surgical Use:

A

Neuroleptoanesthesia: Droperidol (short-acting and highly sedating) + fentanyl

Pre-Surgical Use: Older APDs (with H1 blockade) used due to strong anti-emetic effects (via CTZ and GI), sedation and relief of pruritis (itching)

61
Q

Other Uses of APDs
Depression and Bipolar Disorder:

Atypical APDs:

A

Depression and Bipolar Disorder: some justification for the use of APDs in treatment

Atypical APDs: FDA-approved for acute mania and mixed episodes of BPD

62
Q

Other Uses of APDs
Depression and Bipolar Disorder

Risperidone/Lithium Combination:
Atypical APD + Antidepressants:

A

Risperidone/Lithium Combination: FDA-approved for maintenance in refractory BPD

Atypical APD + Antidepressants: tested for drug-refractory depression (fluoxetine/olanzapine tested first); mixed results depending on the drug combination used

63
Q

Agitation in Alzheimer’s Disease and Dementias

Rationale:
Black Box Warning:

A

Rationale: calming, sedative, antipsychotic effects

Black Box Warning: both typical and atypical APDs increase death due to CV accidents and infections in patients with AD/dementia (therefore, really need to be careful/limit use in this population)

64
Q

Control of Aggressive Behavior in Pediatrics

Risperidone:
Quetiapine and Aripiprazole:

A

Risperidone: FDA-approved for use in autistic children over the age of 5 with aggression or self-injurious behavior

Quetiapine and Aripiprazole: FDA-approved for children over the age of 10 with BPD

65
Q

Control of Aggressive Behavior in Pediatrics

General Issues:

A

Use especially high in Medicaid children (poor)- especially off label use for ADHD (cheaper than the drugs for ADHD)

Off-label use in privately insured children aged 2-5 has also doubled

Pharm Exam 2 (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions